Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
View through CrossRef
Abstract
Objectives
There is lack of clarity regarding the role of angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi) in interfering with the SARS-COV-2 binding on human cells and the resulting change in disease severity. We sought to assess the risk of hospitalization for COVID-19 and serious complications in current users of ARB or ACEi compared to users of dihydropyridine calcium channel blockers (dhpCCB).
Design
Cohort study
Setting
The analysis used de-identified, patient level data from HealthVerity, linking longitudinal data from US medical and pharmacy claims, which contain information on inpatient or outpatient diagnoses, procedures and medication dispensing.
Participants
We identified patients aged 40+ and free of chronic kidney disease (CKD) who were newly diagnosed COVID-19, between March 1, 2020 and May 30, 2020, and adherent to ACEi, ARB, or dhpCCB therapy.
Interventions
Current use of an ACEi, ARB, or dhpCCB.
Main outcome measures
We compared the 30-day risk of hospitalization for COVID-19 and serious complications.
Results
Of 24,708 patients identified, 7,571 were current users of an ARB, 8,484 of an ACEi, and 8,653 of a dhpCCB. The unadjusted 30-day risk of hospitalization for COVID-19 was 2.66% among ARB users, and 2.90% among ACEi users and 3.68% in dhpCCB users. In the PS-matched cohort, the risk of hospitalization among ARB users was 17% lower as compared to dhpCCB (RR=0.83; 0.68-1.00), and the risk among ACE users was 10% lower as compared to dhpCCB (RR=0.90; 0.76-1.07). When including patients with pre-existing CKD, the protective effect of ARB (RR= 0.74; 0.62-0.88) and ACEi (RR=0.84; 0.71-0.99) was more pronounced.
Conclusions
This cohort study showed that neither ARB nor ACEi use increase the risk of severe COVID-19 disease among those infected, and instead suggests that current use of ARB may offer a protective effect. This study found no evidence to support the discontinuation of ARB/ACEi therapy.
Title: Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
Description:
Abstract
Objectives
There is lack of clarity regarding the role of angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi) in interfering with the SARS-COV-2 binding on human cells and the resulting change in disease severity.
We sought to assess the risk of hospitalization for COVID-19 and serious complications in current users of ARB or ACEi compared to users of dihydropyridine calcium channel blockers (dhpCCB).
Design
Cohort study
Setting
The analysis used de-identified, patient level data from HealthVerity, linking longitudinal data from US medical and pharmacy claims, which contain information on inpatient or outpatient diagnoses, procedures and medication dispensing.
Participants
We identified patients aged 40+ and free of chronic kidney disease (CKD) who were newly diagnosed COVID-19, between March 1, 2020 and May 30, 2020, and adherent to ACEi, ARB, or dhpCCB therapy.
Interventions
Current use of an ACEi, ARB, or dhpCCB.
Main outcome measures
We compared the 30-day risk of hospitalization for COVID-19 and serious complications.
Results
Of 24,708 patients identified, 7,571 were current users of an ARB, 8,484 of an ACEi, and 8,653 of a dhpCCB.
The unadjusted 30-day risk of hospitalization for COVID-19 was 2.
66% among ARB users, and 2.
90% among ACEi users and 3.
68% in dhpCCB users.
In the PS-matched cohort, the risk of hospitalization among ARB users was 17% lower as compared to dhpCCB (RR=0.
83; 0.
68-1.
00), and the risk among ACE users was 10% lower as compared to dhpCCB (RR=0.
90; 0.
76-1.
07).
When including patients with pre-existing CKD, the protective effect of ARB (RR= 0.
74; 0.
62-0.
88) and ACEi (RR=0.
84; 0.
71-0.
99) was more pronounced.
Conclusions
This cohort study showed that neither ARB nor ACEi use increase the risk of severe COVID-19 disease among those infected, and instead suggests that current use of ARB may offer a protective effect.
This study found no evidence to support the discontinuation of ARB/ACEi therapy.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
ALDOSTERONE IS A VASCULAR CALCIFICATION PROMOTING FACTOR
ALDOSTERONE IS A VASCULAR CALCIFICATION PROMOTING FACTOR
Objectives
Aim: To observe aortic and cardiac aldosterone expression and its receptor changes in rats with vascular calcification, and exogenous aldosterone effec...
Interrelationships Between Angiotensin, Norepinephrine, Epinephrine, Aldosterone Secretion, and Electrolyte Metabolism in Man
Interrelationships Between Angiotensin, Norepinephrine, Epinephrine, Aldosterone Secretion, and Electrolyte Metabolism in Man
Oversecretion of aldosterone is a consistent finding in the syndrome of malignant hypertension. Infusion of angiotensin has been consistently shown to induce an increased secretion...
PERAN KOMPLEKS JUKSTAGLOMERULUS TERHADAP RESISTENSI PEMBULUH DARAH
PERAN KOMPLEKS JUKSTAGLOMERULUS TERHADAP RESISTENSI PEMBULUH DARAH
Abstract: As the main structural component of the renin-angiotensin-aldosterone system (RAAS), the juxtaglomerular complex plays a very important role in the regulation of vascular...
Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease
Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease
Mitral valvular disease is strongly related to atrial fibrillation (AF), but the different types of mitral valvular disease have a different prevalence of AF. In this study we expl...
Insured-non-insured disparity of catastrophic health expenditure in Northwest Ethiopia: a multivariate decomposition analysis
Insured-non-insured disparity of catastrophic health expenditure in Northwest Ethiopia: a multivariate decomposition analysis
Abstract
Background
Financial risk protection is one indicator of universal health coverage (UHC). All people should be protected from financial ris...
Renin activates PI3K‐Akt‐eNOS signalling through the angiotensin AT1and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii
Renin activates PI3K‐Akt‐eNOS signalling through the angiotensin AT1and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii
BACKGROUND AND PURPOSEThe renin‐angiotensin system (RAS) is critical for the control of blood pressure by the CNS. Recently, direct renin inhibitors were approved as antihypertensi...